RG
VRTX icon

Renaissance Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Renaissance Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Sell
1,008
-64
-6% -$28.4K 0.02% 184
2026
Q1 		$479K Sell
1,072
-361
-25% -$168K 0.02% 187
2025
Q4 		$650K Sell
1,433
-35
-2% -$15.1K 0.03% 180
2025
Q3 		$575K Sell
1,468
-51
-3% -$21.3K 0.02% 183
2025
Q2 		$676K Sell
1,519
-195
-11% -$89.9K 0.03% 173
2025
Q1 		$831K Sell
1,714
-1,468
-46% -$684K 0.04% 172
2024
Q4 		$1.28M Sell
3,182
-42
-1% -$19.5K 0.05% 167
2024
Q3 		$1.5M Sell
3,224
-70,255
-96% -$33.7M 0.06% 160
2024
Q2 		$34.4M Sell
73,479
-4,217
-5% -$1.83M 1.34% 19
2024
Q1 		$32.5M Sell
77,696
-11,236
-13% -$4.75M 1.23% 44
2023
Q4 		$36.2M Sell
88,932
-3,339
-4% -$1.23M 1.5% 10
2023
Q3 		$32.1M Sell
92,271
-1,660
-2% -$581K 1.47% 11
2023
Q2 		$33.1M Sell
93,931
-1,723
-2% -$581K 1.43% 20
2023
Q1 		$30.1M Buy
95,654
+50
+0.1% +$15K 1.38% 25
2022
Q4 		$27.6M Sell
95,604
-748
-0.8% -$228K 1.35% 33
2022
Q3 		$27.9M Sell
96,352
-9,916
-9% -$2.85M 1.5% 8
2022
Q2 		$29.9M Sell
106,268
-29,038
-21% -$7.77M 1.55% 5
2022
Q1 		$35.3M Buy
135,306
+10,191
+8% +$2.42M 1.59% 5
2021
Q4 		$27.5M Buy
125,115
+6,265
+5% +$1.22M 1.12% 48
2021
Q3 		$21.6M Buy
118,850
+17,365
+17% +$3.39M 0.93% 54
2021
Q2 		$20.5M Sell
101,485
-5,095
-5% -$1.07M 0.86% 54
2021
Q1 		$22.9M Buy
106,580
+23,538
+28% +$5.17M 0.97% 54
2020
Q4 		$19.6M Buy
83,042
+4,148
+5% +$952K 0.84% 54
2020
Q3 		$21.5M Sell
78,894
-589
-0.7% -$162K 0.99% 53
2020
Q2 		$23.1M Buy
+79,483
New +$21.5M 1.1% 47

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Renaissance Group's VRTX Position: Q2 2026 in Review

Renaissance Group reduced its Vertex Pharmaceuticals (VRTX) stake by 6% in Q2 2026, selling an estimated $28.4K and leaving 1,008 shares worth $501K. The position accounts for 0.02% of the portfolio, ranked #184.

Renaissance Group first reported a position in VRTX in Q2 2020 and has held it in 25 quarters since. The position peaked at $36.2M in Q4 2023. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Renaissance Group held 1,008 shares of Vertex Pharmaceuticals worth $501K as of Q2 2026.
  • Renaissance Group sold 64 Vertex Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
  • Vertex Pharmaceuticals made up 0.02% of Renaissance Group's portfolio in Q2 2026, its #184 holding.
  • Renaissance Group first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Renaissance Group's Vertex Pharmaceuticals position peaked at $36.2M in Q4 2023.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Renaissance Group's 13F filing for Q2 2026, filed 13 Aug 2026.